"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Reed MK, Smith KR, Ciocco F, Hass RW, Cox AL, Kelly EL, Weinstein LC. Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program. Subst Abuse Treat Prev Policy. 2023 Jan 14; 18(1):4.
-
Sugarman A, Vittitow A, Cheng A, Malone M, McDonald R, Pace N, Williams O, Tofighi B, McNeely J, Schatz D, Roberts T, Hey SP, Garrity K, Lindquist K, Lee JD. Opioid Use Disorder Treatments: An Evidence Map. Drug Alcohol Depend. 2022 Dec 01; 241:109657.
-
Alexander K, Pogorzelska-Maziarz M, Gerolamo A, Hassen N, Kelly EL, Rising KL. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review. Subst Abuse Treat Prev Policy. 2021 08 09; 16(1):60.
-
Stein BD, Jones CM, Smart R, Sheng F, Sorbero M. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18. Drug Alcohol Depend. 2021 04 01; 221:108569.
-
Di Trana A, La Maida N, Tittarelli R, Huestis MA, Pichini S, Busard? FP, Carlier J. Monitoring Prenatal Exposure to Buprenorphine and Methadone. Ther Drug Monit. 2020 04; 42(2):181-193.
-
Niforatos JD, Dorner SC, Pescatore RM, Raja AS. Buprenorphine charges to uninsured patients at top-ranked U.S. hospitals. Am J Emerg Med. 2019 12; 37(12):2253-2254.
-
Wachman EM, Warden AH, Thomas Z, Thomas-Lewis JA, Shrestha H, Nikita FNU, Shaw D, Saia K, Schiff DM. Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. Drug Alcohol Depend. 2018 11 01; 192:45-50.
-
Weinstein ZM, Gryczynski G, Cheng DM, Quinn E, Hui D, Kim HW, Labelle C, Samet JH. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug Alcohol Depend. 2018 08 01; 189:166-171.
-
Kelly MM, Reilly E, Qui?ones T, Desai N, Rosenheck R. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration. Drug Alcohol Depend. 2018 02 01; 183:111-117.
-
Kraft WK. Buprenorphine in Neonatal Abstinence Syndrome. Clin Pharmacol Ther. 2018 Jan; 103(1):112-119.